OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutt

OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich pa

HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and m

US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consu

H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers i

The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook a

Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-mar

HIVE: 9% | HIVE's BUZZ HPC Signs $350M Five-Year AI Cloud Deal With Investment-Grade Customer, A

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutt

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutt

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 result

Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session.

OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript

OmniAb NASDAQ: OABI reported higher second-quarter revenue and a narrower net loss as milestone paym

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Est

OmniAb (NASDAQ:OABI) raises FY2026 sales outlook from $28.000 million-$33.000 million to $32.000 mil

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.05) per share which beat the analyst consensus

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutt

VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader

ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), a

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutt

OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discover

OmniAb NASDAQ: OABI reported first-quarter 2026 results that management characterized as a “very str

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Est

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported fina

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced tha

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financi

OmniAb, Inc. (NASDAQ: OABI - Get Free Report) CEO Matthew Foehr sold 19,244 shares of the business's

OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.11) per share which missed the analyst consens

OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners ("ArrowMark") today announced the signing

OmniAb (NASDAQ:OABI) lowers FY2025 sales outlook from $20.000 million-$25.000 million to $18.000 mil

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.14) per share which met the analyst consensus

RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers th

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.15) per share which beat the analyst consensus

OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.000 million-$25.000 million to $20.000 mi

Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $6 pr

OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.00 million-$25.00 million to $20.00 milli

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.17) per share which missed the analyst consens